It has been well established that human papilloma virus (HPV) is closely linked to numerous cancers. Recently, evidence has been uncovered that show a link between HPV and prostate cancer. This provides us with more evidence that preventing these infections with the HPV vaccine can lead to a reduction in many types of cancers in both men and women.
Plant estrogens (phytoestrogens) were first identified in the early 1930s. At that time it was discovered that soybeans, willows, dates, and pomegranates contained compounds that were much like estrogens. Scientists began studying the role isoflavones play in reducing breast cancer risk in the 1960s. In a 1981 prospective study in Japan, researchers found that daily intake of miso, a soybean paste, was linked to lower death rates from stomach cancer in more than 260,000 men and women. Around that time, other studies on soy began to be published in the United States. In October 1999, the U.S. Food and Drug Administration (FDA) agreed to allow health claims about soy’s role in reducing heart disease on food products containing soy protein. Continue reading “Soy supplements and prostate cancer–no effect”
You’ve probably seen their commercials spread over all of the major TV networks. Beautiful scenes. Well-kept hospitals which often to appear to be near empty. And an anecdote or two or three from presumably real patients who describe their experience at Cancer Treatment Centers of America (CTCA), a private, for-profit operator of cancer treatment hospitals and outpatient clinics which provide both conventional and alternative medical treatments. Included in their treatment plans are chiropractic and naturopathy, neither of which have any evidence whatsoever in providing any healthcare benefit to patients, let alone those suffering from cancer.
Reuters recently published an in-depth report on the validity of the claims that are made by CTCA in its advertising. Here are some of the ones specifically mentioned:
For breast cancer, CTCA claims that its survival rate after 3.5 years post-diagnosis is about 42%, compared to the National Cancer Institute’s SEER (Surveillance Epidemiology and End Results) Program result (more or less a nationwide average) of about 29%. That’s a 13% improvement.